Log in

Codexis Stock Price, Forecast & Analysis (NASDAQ:CDXS)

$15.22
+0.05 (+0.33 %)
(As of 11/14/2019 01:56 AM ET)
Today's Range
$15.00
Now: $15.22
$15.30
50-Day Range
$13.09
MA: $13.80
$15.50
52-Week Range
$12.68
Now: $15.22
$23.05
Volume251,100 shs
Average Volume405,162 shs
Market Capitalization$890.64 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.09
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. Read More…

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CDXS
CUSIP19200510
Phone650-421-8100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60.59 million
Book Value$1.04 per share

Profitability

Net Income$-10,880,000.00

Miscellaneous

Employees132
Market Cap$890.64 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.


Codexis (NASDAQ:CDXS) Frequently Asked Questions

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) announced its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.10. The biotechnology company had revenue of $21.91 million for the quarter, compared to analysts' expectations of $16.56 million. Codexis had a negative return on equity of 15.24% and a negative net margin of 17.85%. View Codexis' Earnings History.

When is Codexis' next earnings date?

Codexis is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Codexis.

What price target have analysts set for CDXS?

5 analysts have issued 1-year price targets for Codexis' stock. Their forecasts range from $19.00 to $25.00. On average, they anticipate Codexis' share price to reach $22.30 in the next twelve months. This suggests a possible upside of 46.5% from the stock's current price. View Analyst Price Targets for Codexis.

What is the consensus analysts' recommendation for Codexis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Codexis.

What are Wall Street analysts saying about Codexis stock?

Here are some recent quotes from research analysts about Codexis stock:
  • 1. According to Zacks Investment Research, "Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. " (11/8/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating of CDXS and our 12-month price target of $16.50 per share. We derive our price target based on the average of three valuation methods: 1) price-sales multiple analysis applying a 3x multiple to our 2025 risk-adjusted revenue estimate discounted at 12%; 2) price-earnings multiple analysis applying a 23x multiple to our 2025 estimated earnings discounted at 12%; and 3) discounted free cash flow analysis assuming a 12% discount rate and a 2% terminal growth rate." (1/14/2019)

Has Codexis been receiving favorable news coverage?

News stories about CDXS stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Codexis earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Codexis.

Are investors shorting Codexis?

Codexis saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,380,000 shares, an increase of 7.0% from the September 15th total of 5,030,000 shares. Based on an average trading volume of 459,800 shares, the short-interest ratio is presently 11.7 days. Currently, 10.1% of the company's stock are short sold. View Codexis' Current Options Chain.

Who are some of Codexis' key competitors?

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), General Electric (GE), Cisco Systems (CSCO), ImmunoGen (IMGN), Crispr Therapeutics (CRSP) and IQIYI (IQ).

Who are Codexis' key executives?

Codexis' management team includes the folowing people:
  • Mr. John J. Nicols, Pres, CEO & Director (Age 55)
  • Mr. Gordon T. B. Sangster, Sr. VP & CFO (Age 66)
  • Dr. James J. Lalonde, Sr. VP of R&D (Age 58)
  • Ms. Laurie Heilmann, Sr. VP of Bus. Devel. & Marketing
  • Prof. Gerhard N. Mayr, Special Advisor to the Board (Age 73)

Who are Codexis' major shareholders?

Codexis' stock is owned by a number of of retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (2.40%), Sumitomo Mitsui Trust Holdings Inc. (2.40%), Assenagon Asset Management S.A. (0.55%), Essex Investment Management Co. LLC (0.31%), SG Americas Securities LLC (0.29%) and State of New Jersey Common Pension Fund D (0.22%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Michael D Aldridge, Pam P Cheng, Patrick Y Yang and Thomas R Baruch. View Institutional Ownership Trends for Codexis.

Which major investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Strs Ohio and Great West Life Assurance Co. Can. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Patrick Y Yang and Thomas R Baruch. View Insider Buying and Selling for Codexis.

Which major investors are buying Codexis stock?

CDXS stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Assenagon Asset Management S.A., SG Americas Securities LLC, State of New Jersey Common Pension Fund D, Roubaix Capital LLC, California Public Employees Retirement System and Comprehensive Portfolio Management LLC. Company insiders that have bought Codexis stock in the last two years include John J Nicols and Patrick Y Yang. View Insider Buying and Selling for Codexis.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $15.22.

How big of a company is Codexis?

Codexis has a market capitalization of $890.64 million and generates $60.59 million in revenue each year. The biotechnology company earns $-10,880,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe.View Additional Information About Codexis.

What is Codexis' official website?

The official website for Codexis is http://www.codexis.com/.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]


MarketBeat Community Rating for Codexis (NASDAQ CDXS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  280 (Vote Outperform)
Underperform Votes:  293 (Vote Underperform)
Total Votes:  573
MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe CDXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel